273 related articles for article (PubMed ID: 23725285)
1. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
2. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ
Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861
[TBL] [Abstract][Full Text] [Related]
3. Impaired generation of bone marrow CD34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome.
Micheva I; Thanopoulou E; Michalopoulou S; Kakagianni T; Kouraklis-Symeonidis A; Symeonidis A; Zoumbos N
Br J Haematol; 2004 Sep; 126(6):806-14. PubMed ID: 15352984
[TBL] [Abstract][Full Text] [Related]
4. Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
Ivy KS; Brent Ferrell P
Curr Hematol Malig Rep; 2018 Aug; 13(4):244-255. PubMed ID: 29934935
[TBL] [Abstract][Full Text] [Related]
5. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
6. Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes.
Dreyssig J; Kremser A; Liepert A; Grabrucker C; Freudenreich M; Schmid C; Kroell T; Scholl N; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer HM
Immunotherapy; 2011 Sep; 3(9):1113-24. PubMed ID: 21913833
[TBL] [Abstract][Full Text] [Related]
7. Innate immune signaling in the myelodysplastic syndromes.
Starczynowski DT; Karsan A
Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
[TBL] [Abstract][Full Text] [Related]
8. The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes.
Wang Z; Tang X; Xu W; Cao Z; Sun L; Li W; Li Q; Zou P; Zhao Z
PLoS One; 2013; 8(3):e57470. PubMed ID: 23469196
[TBL] [Abstract][Full Text] [Related]
9. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
Warlick ED; Miller JS
Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes: the pediatric point of view.
Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F
Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722
[TBL] [Abstract][Full Text] [Related]
13. Therapy-related myelodysplastic syndrome.
Candelaria M; Dueñas-Gonzalez A
Expert Opin Drug Saf; 2015 May; 14(5):655-65. PubMed ID: 25675961
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM
Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293
[TBL] [Abstract][Full Text] [Related]
15. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology.
Disperati P; Ichim CV; Tkachuk D; Chun K; Schuh AC; Wells RA
Leuk Res; 2006 Feb; 30(2):233-9. PubMed ID: 16046234
[TBL] [Abstract][Full Text] [Related]
16. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DC
Ansprenger C; Amberger DC; Schmetzer HM
Clin Immunol; 2020 Aug; 217():108467. PubMed ID: 32464186
[TBL] [Abstract][Full Text] [Related]
17. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
[TBL] [Abstract][Full Text] [Related]
18. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells in MDS and AML--cause, effect or solution to the immune pathogenesis of disease?
Panoskaltsis N
Leukemia; 2005 Mar; 19(3):354-7. PubMed ID: 15674424
[No Abstract] [Full Text] [Related]
20. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
